Hypermethylation-Modulated Downregulation of Claudin-7 Expression Promotes the Progression of Colorectal Carcinoma

Fumihito Nakayama^a Shuho Semba^a Yu Usami^a Hideki Chiba^b
Norimasa Sawada^b Hiroshi Yokozaki^a

^aDivision of Pathology, Department of Pathology and Microbiology, Kobe University Graduate School of Medicine, Kobe, and ^bDepartment of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan

Key Words

Claudin-7 · Promoter hypermethylation · 5-aza-2'-deoxycytidine · Lymph node metastasis · Colorectal cancer

Abstract

Objective: The expression of tight junction-related transmembrane protein claudin-7 (CLDN7) and its regulatory mechanism were investigated in colorectal carcinomas (CRCs). **Methods:** Methylation-specific polymerase chain reaction and treatment with the demethylating agent 5-aza-2'-deoxycytidine were conducted to analyze the methylation status at the *CLDN7* promoter region in the Colo320 CRC cell line. We used a total of 26 stage 0 CRCs with an adenoma component and 90 invasive CRCs (stage I–IV), as well as their corresponding lymph node metastases, in an immunohistochemical study. **Results:** In Colo320 (CLDN7-negative) cells, hypermethylation at the *CLDN7* promoter was detected and treatment with 5-aza-2'-deoxycytidine restored *CLDN7* expression. In CRC tissues, decreased CLDN7 expression was detected in 62% of stage 0 CRCs and 80% of stage I–IV CRCs, compared with their adjacent adenoma lesions and nonneoplastic epithelia, which had a close correlation with the incidence of vessel infiltration and clinicopathologic stage. Hy-

permethylation at the *CLDN7* promoter was detected in 20% of CRCs with low CLDN7 expression. However, CLDN7 expression tended to be re-expressed in their corresponding lymph node metastases. **Conclusion:** These findings suggest that the *CLDN7* gene silencing by promoter hypermethylation and the resultant reduction of CLDN7 expression may play an important role in the progression of CRCs.

Copyright © 2008 S. Karger AG, Basel

Introduction

Metastasis is the primary cause of death from colorectal carcinoma (CRC) and consists of a series of sequential steps, all of which must be successfully completed for metastasis to occur: (1) the shedding of cells from a primary tumor into the circulation; (2) survival of the cells in the circulation; (3) arrest in a new organ; (4) extravasation into the surrounding tissue; (5) initiation and maintenance of growth; and (6) vascularization of the metastatic tumor [1]. Among these steps in the process of metastasis, the loss of cell-to-cell adhesion in the neoplastic epithelium is the initial step [2]; therefore, understanding the mechanism(s) through which the infiltration and/or

metastatic potential of cancer cells may increase is required if a novel strategy for controlling human malignancies is to be developed. The junctional complex of simple epithelial cells located at the most apical part of the lateral membrane consists of three components: tight junctions (TJs), adherens junctions and desmosomes [3]. Although adherens junctions and desmosomes mechanically link adjacent cells, TJs are responsible for intercellular sealing, resulting in their barrier function and paracellular transport [4]. In addition, TJs have been shown to influence various signaling pathways that regulate epithelial differentiation, proliferation and migration [3, 4].

Claudins are a family of transmembrane proteins that contains four transmembrane domains and two extracellular loops, which form the backbone of TJ strands by binding the homophilic and/or heterophilic interactions [4, 5]. The intracellular component of claudins is responsible for protein-protein interactions with the other TJ molecules, such as ZO-1 and occludin [6]. The modulation of claudin expression is closely associated with the oncogenic transformation of cells, and the loss of normal TJ functions is therefore believed to constitute a hallmark of human carcinomas [7]. Indeed, altered expression of claudins has been documented in CRC: Overexpression of claudin-1, claudin-8 and claudin-12 is frequently detected in primary CRCs and liver metastases [8, 9], whereas claudin-4 expression is downregulated in a large fraction of CRCs [10]. Although the mechanism of these alterations of claudin expression has not yet been explored, these findings indicate that altered claudin expression may play a critical role in the activities of invading and metastasizing CRC cells.

Recent reports suggest that the disruption of TJ protein expression can represent the onset of the epithelial-mesenchymal transition (EMT), which promotes cell motility and invasiveness [11]. We have previously demonstrated that the loss of claudin-4 expression was detected in CRCs and the siRNA-mediated claudin-4 knockdown in SW480 claudin-4-positive CRC cells up-regulated cell motility, suggesting that the disruption of claudin-4-mediated TJ construction enhances cancer cell invasion and metastasis in CRCs [10]. In this study, we examined claudin-7 (CLDN7) expression in CRCs to determine the relationship between their expression and clinicopathological findings. In particular, we focused on the incidence of lymph node metastasis, since the reduction of CLDN7 expression at the invasive front of esophageal cancer was significantly associated with the depth of invasion, lymphatic vessel infiltration and lymph node

metastasis [12]. Furthermore, the methylation status of CLDN7 promoter was investigated to reveal the mechanism which controls CLDN7 expression levels during the progression and development of CRCs.

Materials and Methods

Cell Culture and Treatment

Human colon cancer cell lines (DLD-1, SW480, LoVo, TCO, Colo201 and Colo320) were obtained from American Type Culture Collection (Manassas, Va., USA), Cell Resource Center for Biomedical Research (Sendai, Japan) and Health Science Research Bank (Osaka, Japan). Cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum at 37°C in an atmosphere containing 5% CO₂. Colo320 cells were seeded in a 100-mm plate at a density of 1×10^6 cells. After 24 h, cells were treated with DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-dC; Sigma-Aldrich, St. Louis, Mo., USA) and histone deacetylase inhibitor trichostatin A (TSA; Sigma-Aldrich), either alone or in combination. The medium was changed every day for 5 days. For the treatment combining 5-aza-dC and TSA, cells were cultured in the presence of 5-aza-dC (0–25 µM) for 4 days and were subsequently treated with TSA (50 ng/ml) for another 24 h.

Reverse Transcription-Polymerase Chain Reaction

Reverse transcription-polymerase chain reaction (RT-PCR) was performed using the OneStep RT-PCR kit (Qiagen, Hilden, Germany). Primers for RT-PCR amplification were as follows: CLDN7, 5'-CCA CTC GAG CCC TAA TGG TG-3' (forward)/5'-GGT ACC CAG CCT TGC TCT CA-3' (reverse), and G3PDH, 5'-ACC ACA GTC CAT GCC ATC AC-3' (forward)/5'-TCC ACC ACC CTG TTG CTG TA-3' (reverse) [13]. After initial step at 50°C for 30 min, cDNA was amplified for 25 cycles. RT-PCR products underwent electrophoresis.

Western Blot Analysis

Cells were lysed in lysis buffer [50 mM Tris-HCl (pH 7.4), 125 mM NaCl, 0.1% Triton-X and 5 mM EDTA] and a protease inhibitor (Sigma-Aldrich). Proteins from each cell line were separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis, electrotransferred onto an Immobilon-P membrane (Millipore, Billerica, Mass., USA), and then immunoblotted with rabbit polyclonal antibodies against CLDN7 (1:1,000 dilution; Zymed, San Francisco, Calif., USA). Mouse monoclonal antibody to β-actin (1:1,000 dilution; Sigma-Aldrich) was used for loading control. Horseradish peroxidase-conjugated donkey anti-mouse IgG and sheep anti-rabbit IgG (GE Healthcare, Piscataway, N.J., USA) were used as secondary antibodies. Proteins were visualized using enhanced chemiluminescence.

Immunofluorescence

Cells plated in eight-chamber slides were fixed in 100% methanol and were incubated with the following rabbit monoclonal CLDN7 antibody (1:1,000 dilution). Cells were then incubated in RPMI-1640 medium with anti-rabbit fluorescein isothiocyanate-conjugated antibody (Jackson, West Grove, Pa., USA). 4',6-diamidino-2-phenylindole (DAPI) was used for staining of the nuclei.

Methylation-Specific PCR Analysis

Genomic DNA (1 µg) extracted from tissue samples or cell lines was denatured by 0.3 M NaOH for 10 min at 37°C, and the samples were incubated at 50°C for 16 h after adding hydroquinone (Sigma-Aldrich) and sodium bisulfate (Wako Pure Chemicals, Osaka, Japan). Methylation-specific PCR (MSP) was performed to analyze the methylation status at CpG-rich area in the *CLDN7* promoter (−831 to −330 bp) as described elsewhere [13]. Primers specific for unmethylated DNA and methylated DNA were as follows: unmethylated DNA, 5'-TGG GGA AAG GGT GGT GTT G-3' (forward)/5'-TTA CCC AAT TTT AAC CAC CAC-3' (reverse), and methylated DNA, 5'-GAC GTT AGG TTA TTT TCG GTC-3' (forward)/5'-AAA CGC GTT TCT AAA CGC CG-3' (reverse). PCR was carried out for 35 cycles at 95°C for 30 s, 60°C for 30 s, followed by a final extension at 72°C for 5 min. PCR products were electrophoresed on 8% acrylamide gels. Genomic DNA isolated from DLD-1 cells methylated by *SssI* methylase (New England Biolabs, Ipswich, Mass., USA) was used as a methylation-positive control, and that demethylated by 5-aza-dC was used as a demethylation-positive control.

Bisulfite Genomic Sequence Analysis

Bisulfite sequence analysis was performed to check the methylation status in cell lines. Genomic DNAs extracted were subjected to bisulfite modification and amplified for the 5' region. The primers were designed from regions in which there are no CpG dinucleotides. The PCR products were gel-purified using the QIAquick Gel Extraction (Qiagen) according to the manufacturer's instructions. Each amplified DNA samples was subcloned and applied to the ABI 310 DNA analyzer using BigDye terminator (Applied Biosystems, Foster City, Calif., USA).

Tissue Samples

Formalin-fixed and paraffin-embedded specimens from 26 stage 0 CRCs with an adenoma component and 90 invasive CRCs (stage I–IV) removed at Kobe University Hospital (Kobe, Japan) were employed. Histological subtypes and grade were assigned the criterion of the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus [14] along with the International Union against Cancer Classification [15]. Informed consent was obtained from all patients and the study was approved by the Kobe University Institutional Review Board. These samples were sliced into 4-µm-thick sections for immunohistochemistry and DNA extraction. Nonneoplastic epithelia and adenoma lesions adjacent to these CRCs were also investigated, as well as 42 of corresponding lymph node metastases.

Immunohistochemistry

Deparaffinized and rehydrated sections were autoclaved to retrieve antigenicity. After blocking endogenous peroxidase activity and nonspecific binding, sections were incubated with rabbit polyclonal CLDN7 (1:100 dilution, Zymed) and were then incubated with biotinylated secondary antibody and horseradish peroxidase-conjugated streptavidin reagent (LSAB2 Kit, Dako, Calif., USA) [12]. CLDN7 protein was visualized using 3,3'-diamino-benzidine and sections were then counterstained in hematoxylin. The degree of CLDN7 expression was evaluated according to the number of stained cells and the staining intensity in individual cells: low, almost no CLDN7-positive cells or <30% of tumor cells showed weak immunoreactivity; high, ≥30% of

tumor cells showed intense immunoreactivity. The results of immunohistochemistry were evaluated by three independent observers (F.N., S.S. and Y.U.), and all of the sections were scored twice to confirm the reproducibility of the results. The χ^2 test was used to determine correlations between CLDN7 expression and clinicopathologic findings. A *p* value less than 0.05 was regarded to be statistically significant.

Results

Promoter Hypermethylation-Mediated CLDN7 Downregulation in CRC Cells

To determine whether *CLDN7* mRNA levels reflect protein expression levels, we performed RT-PCR and Western blot analyses on a panel of 6 CRC cell lines. The levels of *CLDN7* expression were almost equivalent to those of *CLDN7* in these CRC cell lines, and membranous distribution of *CLDN7* was detected by immunofluorescence (fig. 1A–C). Since promoter hypermethylation impedes *CLDN7* expression in breast cancers [13], we analyzed the methylation status at the *CLDN7* promoter CpG sites. Colo320 cells did not express either *CLDN7* in the mRNA or protein levels in accord with hypermethylation at the *CLDN7* promoter CpG sites (fig. 1D). An identical result was obtained from MSP analysis using another MSP primer set (data not shown). In addition, we validated the results of MSP analysis by sequencing of the bisulfite-treated genomic DNAs (fig. 1E).

To investigate if hypermethylation-mediated silencing of *CLDN7* expression is functional, treatment with 5-aza-dC demethylating agent in the presence or absence of TSA DNA methyltransferase inhibitor was attempted in Colo320 cells. Treatment with 5-aza-dC promoted demethylation of the *CLDN7* promoter along with increased *CLDN7* mRNA expression in a dose-dependent manner, irrespective of additional TSA treatment (fig. 2).

Reduced CLDN7 Expression Is Associated with the Progression of CRCs

Next, we investigated altered *CLDN7* expression in stage 0 CRCs with an adenoma component to clarify the significance of *CLDN7* during multistep colorectal carcinogenesis. In normal colorectal epithelia, *CLDN7* expression was clearly detected around the cell membrane of the basal crypt region as well as that of the superficial crypt region (fig. 3A), a result that was similar to that of the other claudin family members [9, 10, 16]. Although *CLDN7* expression was relatively retained in adenoma lesions, the frequency of the downregulation of *CLDN7* expression was significantly higher in the adjacent stage

Fig. 1. Suppression of *CLDN7* expression is associated with the *CLDN7* promoter hypermethylation in Colo320 CRC cells. **A** Expression of *CLDN7* in CRC cell lines determined by RT-PCR analysis. β -Actin was used as loading control. **B** Expression of *CLDN7* in CRC cell lines determined by Western blot analysis. β -Actin was used as loading control. **C** Results of immunofluorescence of *CLDN7* expression in CRC cell lines. Membranous localization of *CLDN7* was confirmed. Nuclei were stained with DAPI. **D** *CLDN7* promoter region methylation status in CRC cell lines. DNAs extracted from each CRC cell line were treated with sodium bisulfate. U = Unmethylated; M = methylated. **E** Results of bisulfite genomic sequence analysis. **a** Methylation status of the *CLDN7* promoter in DLD-1 and Colo320 cells. Filled boxes indicate methylation; open boxes indicate absence of methylation. **b** Representative results of bisulfite genomic sequence analysis. Asterisks indicate the CpG islands.

0 CRC lesions [adenoma, 4 (15%) cases, and stage 0 CRC, 16 (62%) cases; $p = 0.004$]; some CRC cases with decreased *CLDN7* expression demonstrated *CLDN7* promoter hypermethylation (fig. 3A).

The expression of *CLDN7* was then examined to clarify its role during the progression of CRCs. Among 90

invasive CRCs (stage I–IV), decreased *CLDN7* expression was frequently [72 (80%) cases] detected, a frequency that was much higher than that in adjacent normal mucosa and adenomas. Interestingly, 18 (20%) of 90 invasive CRCs demonstrated remarkably lower *CLDN7* expression at the invasive front than in superficial areas (fig. 3B).

Fig. 2. Restoration of *CLDN7* expression by treatment with 5-aza-dC in Colo320 CRC cells. **A** Results of MSP assay after treatment with 5-aza-dC and TSA. Treatment with 5-aza-dC demethylated at the *CLDN7* promoter region. U = Unmethylated; M = methylated. **B** Treatment with 5-aza-dC increased *CLDN7* expression levels in a dose-dependent manner. Results of RT-PCR analysis (upper panel) were numerated by the intensity of each band (lower panel).

No statistical significance was detected in the clinicopathologic findings; however, reduced *CLDN7* expression was correlated with the presence of infiltration into lymphatic ($p = 0.027$) and venous vessels ($p = 0.009$) as well as clinicopathologic stage ($p = 0.033$; table 1). The incidence of lymph node metastasis and distant metastasis tended to be higher in CRCs with low levels of *CLDN7* expression. To investigate the relationship between the reduction of *CLDN7* expression and DNA hypermethylation at the *CLDN7* promoter sites, we performed the MSP analysis in these invasive CRC cases. Among 45 informative tumors with low *CLDN7* expression, 9 (20%) cases demonstrated methylated *CLDN7* gene products, whereas no methylation of the *CLDN7* promoter was present in 14 tumors with high *CLDN7* ($p = 0.069$; data not shown).

Forty-two CRCs with lymph node metastasis were employed to compare *CLDN7* expression in primary CRCs and matched lymph node metastatic lesions. In primary CRCs, 37 (88%) cases exhibited low *CLDN7* expression; however, decreased *CLDN7* expression in lymph node

metastases was detected only in 21 (50%) cases ($p < 0.001$; fig. 4). We confirmed demethylation of the *CLDN7* promoter in several metastatic lesions of these lymph nodes (fig. 4A).

Discussion

Much is known regarding the function of claudins in the maintenance of normal glandular epithelial cell homeostasis; however, their role in the process of tumorigenesis is less elucidated. The exact biological significance of altered claudin expression in cancer remains unknown. For example, a decrease or loss of claudin-4 expression has been documented in various human malignancies, including those of the breast [17], stomach [18], colon [10], and urinary bladder [19]; however, claudins are overexpressed in uterine [20] and ovarian cancers [21]. In the present study, we analyzed stage 0 CRCs and their corresponding adenoma lesions to evaluate changes of *CLDN7* expression in the transition from ad-

Fig. 3. Reduced expression of CLDN7 in CRC tissue samples. **A** Expression of CLDN7 in nonneoplastic mucosa (a), adenoma lesion (b) and stage 0 CRC (c). The *CLDN7* methylation status in each component is demonstrated. U = Unmethylated; M = methylated. **B** Heterogenous expression of CLDN7 in invasive CRC and adjacent adenoma lesion (a). At the surface of invasive CRC, CLDN7 expression was slightly decreased (b), which was significant at the invasive front (c).

enoma to cancer. In these cases, CRCs are thought to have developed from adjacent adenomas, but the incidence of the reduction of CLDN7 in stage 0 CRCs was much higher than in adenomas, suggesting that the downregulation of CLDN7 is a key event during the malignant transformation of CRCs. In addition, this downregulation at the invasive front of CRCs was closely correlated with tumor infiltration into the lymphatic and venous vessels, and with clinicopathologic stage, strong-

ly supporting the biological significance of CLDN7 reduction in the progression of CRCs. According to these results, we attempted to evaluate the alteration of CLDN7 expression on the process of vessel infiltration; however, no significant change was found in cancer cells between inside and outside of the lymphatic or venous vessels (data not shown). Several hypotheses have been suggested to explain the impact of the disruption of TJs, consequently resulting in the increased accessibility of the tu-

Table 1. Expression of CLDN7 in CRCs: relationship with clinicopathologic findings

	CLDN7 expression ¹		p value ²
	low	high	
Total	72 (80%)	18 (20%)	
Location ³			
Proximal	42 (75%)	14 (25%)	0.128
Distal	30 (88%)	4 (12%)	
Tumor size			
≤25 mm	19 (68%)	9 (32%)	0.098
>25 mm	53 (85%)	9 (15%)	
Histologic type ⁴			
W	23 (70%)	10 (30%)	0.063
P	49 (86%)	8 (14%)	
Depth of invasion			
T1/T2	24 (75%)	8 (25%)	0.378
T3/T4	48 (82%)	10 (18%)	
Vessel infiltration			
Lymphatic vessels			
Present	55 (86%)	9 (14%)	0.027*
Absent	17 (65%)	9 (35%)	
Venous vessels			
Present	48 (89%)	6 (11%)	0.009*
Absent	24 (67%)	12 (33%)	
Distant metastasis			
Lymph node			
Present	37 (88%)	5 (12%)	0.073
Absent	35 (73%)	13 (27%)	
Other organs			
Present	13 (93%)	1 (7%)	0.191
Absent	59 (78%)	17 (22%)	
Stage			
I/II	28 (70%)	12 (30%)	0.033*
III/IV	44 (88%)	6 (12%)	

¹ Immunoreactivity of CLDN7 was determined as described in the text.

² Statistical analysis was performed by χ^2 test. * $p < 0.05$ (statistically significant).

³ Tumor location was divided into the proximal (cecum-ascending/transverse colon) and distal (descending/sigmoid colon-rectum) colons.

⁴ Histologic types were determined according to the morphological features of each CRC. W = Well-differentiated type; P = poorly differentiated type.

mor cells to nutrients [22], the increased cell proliferation [23], and the increased motility associated with metastasis [24, 25]. Therefore, claudin-mediated TJs are an impediment to the unrestricted cell growth and invasion phenotype in cancer.

Epithelial carcinogenesis is associated with the loss of tissue architecture characterized by the loss of organized

Fig. 4. Re-expression of CLDN7 in lymph node metastases. **A** Representative case of primary CRC with decreased CLDN7 expression and its corresponding lymph node metastatic site with high CLDN7 expression was illustrated. Note that re-expression of CLDN7 in lymph node metastases was accompanied with demethylation of the *CLDN7* promoter CpG sites. U = Unmethylated; M = methylated. **B** A comparative study of expression of CLDN7 in primary CRCs and their corresponding lymph node metastases. White bar = Low CLDN7 expression; black bar = high CLDN7 expression.

cell-cell and cell-matrix adhesions, which allows the migration of malignant cells from their immediate environmental niche. In esophageal squamous cell carcinomas (SCC), CLDN7 expression is often lost or localized to the cytoplasm, with this loss closely correlated with the grade of malignancy [12, 26], suggesting that the dysregulation of membranous CLDN7 expression may be one mechanism for the loss of epithelial architecture and the invasion observed in esophageal SCC. Lioni et al. [26] have demonstrated that knockdown of CLDN7 in SCC cells led not only to a decrease in E-cadherin expression but also to increased cell growth and enhanced invasion into a three-dimensional matrix; conversely, the CLDN7-overexpressing SCC cells became more adhesive and less invasive along with increased E-cadherin expression.

The immunohistochemical study of the expression of CLDN7 in CRC performed in the present study was compatible with the previous reports of Lioni et al. [26]. Increased CLDN7 expression was reported in gastric adenocarcinomas, particularly in their intestinal-type tumors, whereas CLDN7 was localized mainly in the cytoplasm but not in the cellular membrane in gastric adenocarcinomas [27]. Taken together, these results suggest that the mislocalization of CLDN7 may play an important role in the malignant transformation of epithelial cells. The complex consists of epithelial cell adhesion molecule (EpCAM), CLDN7, tetraspanin CO-029, and CD44 variant isoform v6 (CD44v6) recruited into tetraspanin-enriched membrane microdomains. CLDN7 is a key molecule for the EpCAM/CLDN7/CO-029/CD44v6 complex formation [28]. Further investigation will be required to clarify the biological significance of CLDN7 during the progression of CRCs.

In addition to the effect of nonsteroidal anti-inflammatory drug-modulated induction of *CLDN4* expression [29], the *CLDN4* promoter is controlled by epigenetic modifications of the Sp1-containing critical promoter region [30]. In the present study, we detected the methylation-mediated *CLDN7* gene silencing in 20% of the CLDN7-negative CRCs, which was similar to the previous report on invasive breast cancer [13]. Interestingly, suppression of CLDN7 expression by hypermethylation was observed in stage 0 CRCs but not in either adjacent nonneoplastic mucosa or adenoma lesions. To our knowledge, this is the first report that demonstrated downregulation of CLDN7 expression by promoter hypermethylation in CRCs. However, only 20% of invasive CRCs with decreased CLDN7 expression showed hypermethylation in the *CLDN7* promoter CpG sites. This can result from the fact that we only evaluated methylation status of the predicted promoter region (–851 to –330 bp). Since the *CLDN7* regulatory CpG islands may possibly span the promoter region and exon 1 (–851 to 279 bp), we should have analyzed the methylation status of the other CpG island around the predicted promoter region. Furthermore, the levels of CLDN7 expression in metastatic lymph node CRCs were much higher than those in the primary tumors. This discrepancy supports the idea that the loss of CLDN7 expression in the invasive front of primary CRCs was negatively regulated by such epigenetic alterations at the *CLDN7* promoter CpG sites. However, CLDN7 expression might be suppressed by other mechanism(s) in 80% of the CLDN7-negative CRCs. As shown in figure 2, since CLDN7 mRNA level was slightly elevated after treatment with TSA and without 5-aza-

dC, histone acetylation might be involved in the regulation of CLDN7 expression. Ikenouchi et al. [11] reported that the transcription repressor Snail induced EMT with concomitant repression of the expression of claudins and occuldin; Snail binds directly to the E-box of the promoters of the *CLDN* and *occludin* genes, resulting in complete re-expression of their promoter activity. Further investigation is necessary to clarify the other mechanisms by which CLDN7 expression is tightly regulated.

Reduced intercellular adhesion is implicated in the establishment of metastasis as it allows the detachment of the malignant cells from the primary tumors. Indeed, we frequently detected decreased CLDN7 expression in primary CRCs with a close correlation with infiltration into vessels and clinicopathologic findings; however, in lymph node metastases, about a half of the metastatic lesions re-expressed CLDN7. Park et al. [31] examined the expression of the intercellular adhesion molecules, E-cadherin, α -catenin, β -catenin, γ -catenin and CLDN7 in primary breast carcinoma and their corresponding axillary lymph node metastasis and found a significant reduction of these adhesion proteins in primary tumors; nevertheless, re-expression in their axillary lymph node metastases was frequently observed. Although the role of the mechanism of re-expression of these proteins in metastatic sites remains unclear, re-expression of the proteins enables the circulating tumor cells to resettle at the metastatic organs by facilitating the intercellular adhesion process for metastatic tumor progression. In fact, CLDN7 overexpression increases the homotypic adhesion of the TE-8 SCC cells and subsequently leads to the enhancement of spheroid formation, which is likely to be performed by E-cadherin [26]. Since the epithelial differentiation, but not EMT, of cells is characterized by the gaining of cell–cell adhesion and polarity followed by the formation of cytoskeletal organization, the re-expression of CLDN7 may help circulating CRC cells to differentiate into epithelium, after which arrest in a new organ, extravasation into the surrounding tissue, and the initiation and maintenance of growth at metastatic sites take place. It is hoped that a more in-depth understanding of these processes will shed light on how to impede the progression and development of CRCs.

Acknowledgements

Supported by Grant-in-Aid for Scientific Research from the Japan Society for Promotion of Science (C-19590347) and the Terry Fox Run Foundation for Cancer Research.

References

- Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. *Nat Rev Cancer* 2002;2:563–572.
- Shimoyama Y, Nagafuchi A, Fujita S, Gotoh M, Takeichi M, Tsukita S, Hirohashi S: Cadherin dysfunction in a human cancer cell line: possible involvement of loss of α -catenin expression in reduced cell-cell adhesiveness. *Cancer Res* 1992;52:5770–5774.
- Schneeberger EE, Lynch RD: The tight junction: a multifunctional complex. *Am J Physiol Cell Physiol* 2004;286:C1213–C1228.
- Tsukita S, Furuse M, Itoh M: Multifunctional strands in tight junctions. *Nat Rev Mol Cell Biol* 2001;2:285–293.
- Morita K, Furuse M, Fujimoto K, Tsukita S: Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. *Proc Natl Acad Sci USA* 1999;96:511–516.
- Turksen K, Troy TC: Barriers built on claudins. *J Cell Sci* 2004;117:2435–2447.
- Swisselhelm K, Macek R, Kubbies M: Role of claudins in tumorigenesis. *Adv Drug Deliv Rev* 2005;57:919–928.
- Gröne J, Weber B, Staub E, Heinze M, Klamann I, Pilarsky C, Hermann K, Castanos-Velez E, Röpcke S, Mann B, Rosenthal A, Buhr HJ: Differential expression of genes encoding tight junction proteins in colorectal cancer: frequent dysregulation of claudin-1, -8 and -12. *Int J Colorect Dis* 2007;22:651–659.
- Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, Neff J, Washington MK, Beauchamp RD: Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. *J Clin Invest* 2005;115:1765–1776.
- Ueda J, Semba S, Chiba H, Sawada N, Seo Y, Kasuga M, Yokozaki H: Heterogeneous expression of claudin-4 in human colorectal cancer: decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. *Pathobiology* 2007;74:32–41.
- Ikenouchi J, Matsuda M, Furuse M, Tsukita S: Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. *J Cell Sci* 2003;116:1959–1967.
- Usami Y, Chiba H, Nakayama F, Ueda J, Matsuda Y, Sawada N, Komori T, Ito A, Yokozaki H: Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. *Hum Pathol* 2006;37:569–577.
- Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S: Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. *Oncogene* 2003;22:2021–2033.
- Japanese Society for Cancer of Colon and Rectum: General Rules for Clinical Pathological Studies on Cancer of Colon, Rectum and Anus, ed 7. Tokyo, Kanehara Public, 2006.
- Sobin LH, Wittekind CH: UICC TNM Classification of Malignant Tumor, ed 5. New York, John Wiley and Sons, 1997.
- Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT, Collins JE: Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. *Lab Invest* 2005;85:1139–1162.
- Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, Argani P, Sukumar S: *Clostridium perfringens* enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. *Am J Pathol* 2004;164:1627–1633.
- Soini Y, Tommola S, Helin H, Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. *Virchows Arch* 2006;448:52–58.
- Boireau S, Buchert M, Samuel MS, Pannequin J, Ryan JL, Choquet A, Chapuis H, Rebillard X, Avances C, Ernst M, Joubert D, Mottet N, Hollande F: DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma. *Carcinogenesis* 2007;28:246–258.
- Santin AD, Bellone S, Siegel ER, McKenney JK, Thomas M, Roman JJ, Burnett A, Tognon G, Bandiera E, Pecorelli S: Overexpression of *Clostridium perfringens* enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. *Clin Cancer Res* 2007;13:3339–3346.
- Agarwal R, D'Souza T, Morin PJ: Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. *Cancer Res* 2005;65:7378–7385.
- Mullin JM: Potential interplay between luminal growth factors and increased tight junction permeability in epithelial carcinogenesis. *J Exp Zool* 1997;279:484–489.
- Wodarz A: Tumor suppressors: linking cell polarity and growth control. *Curr Biol* 2000;10:R624–R626.
- Ren J, Hamada J, Takeichi N, Fujikawa S, Kobayashi H: Ultrastructural differences in junctional intercellular communication between highly and weakly metastatic clones derived from rat mammary carcinoma. *Cancer Res* 1990;50:358–362.
- Martin TA, Jiang WG: Tight junctions and their role in cancer metastasis. *Histol Histopathol* 2001;16:1183–1195.
- Lioni M, Brafford P, Andl C, Rustgi A, El-Deiry W, Herlyn M, Smalley KS: Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. *Am J Pathol* 2007;170:709–721.
- Johnson AH, Frierson HF, Zaika A, Powell SM, Roche J, Crowe S, Moskaluk CA, El-Rifai W: Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. *Am J Pathol* 2005;167:577–584.
- Kuhn S, Koch M, Nübel T, Ladwein M, Antolovic D, Klingbeil P, Hildebrand D, Moldenhauer G, Langbein L, Franke WW, Weitz J, Zöller M: A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. *Mol Cancer Res* 2007;5:553–567.
- Mima S, Tsutsumi S, Ushijima H, Takeda M, Fukuda I, Yokomizo K, Suzuki K, Sano K, Nakanishi T, Tomisato W, Tsuchiya T, Mizushima T: Induction of claudin-4 by nonsteroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. *Cancer Res* 2005;65:1868–1876.
- Honda H, Pazin MJ, Ji H, Werny RP, Morin PJ: Crucial roles of Sp1 and epigenetic modifications in the regulation of the *CLDN4* promoter in ovarian cancer cells. *J Biol Chem* 2006;281:21433–21444.
- Park D, Karsen R, Axcrone U, Noren T, Sauer T: Expression pattern of adhesion molecules (E-cadherin, α -, β -, γ -catenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis. *APMIS* 2007;115:52–65.